Title: A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection
Subjects: Cost of, Medical care, Pediatric respiratory diseases, Respiratory infections in children, Treatment